Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heparin-induced thrombocytopenia.

K L Kaplan1, C W Francis

  • 1University of Rochester Medical Center, Vascular Medicine Unit, NY 14642, USA. karen_kaplan@urmc.rochester.edu

Blood Reviews
|May 4, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of concomitant factor VII deficiency and Factor V Leiden mutation.

International journal of laboratory hematology·2017
Same author

During warfarin induction, the Fiix-prothrombin time reflects the anticoagulation level better than the standard prothrombin time.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Fiix-prothrombin time monitoring improves warfarin anticoagulation outcome in atrial fibrillation: a systematic review of randomized trials comparing Fiix-warfarin or direct oral anticoagulants to standard PT-warfarin.

International journal of laboratory hematology·2016
Same author

A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma.

Journal of thrombosis and haemostasis : JTH·2016
Same author

ABO-immune complex formation and impact on platelet function, red cell structural integrity and haemostasis: an in vitro model of ABO non-identical transfusion.

Vox sanguinis·2015
Same author

Victor J. Marder, M.D.: physician, scientist, founder, lover of the arts, teacher, leader (1934-2015).

Journal of thrombosis and haemostasis : JTH·2015
Same journal

Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings.

Blood reviews·2026
Same journal

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same journal

PRISMA-based systematic review on iron stores in repeat blood donors.

Blood reviews·2026
Same journal

Artificial intelligence applications in thrombotic thrombocytopenic Purpura: A systematic review of diagnostic, risk stratification, and prognostic models.

Blood reviews·2026
Same journal

Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group.

Blood reviews·2026
Same journal

The Lebanese national patient blood management guidelines: A new page in the medical practice.

Blood reviews·2026
See all related articles

Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin use. Type II HIT involves antibodies against a heparin-platelet factor 4 complex, leading to thrombosis, requiring heparin cessation and alternative anticoagulation.

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Heparin-induced thrombocytopenia (HIT) is an increasingly recognized complication of heparin therapy.
  • Type II HIT is an immune-mediated adverse drug reaction.
  • Thrombosis is a significant risk associated with HIT.

Purpose of the Study:

  • To review the pathophysiology and clinical aspects of type II heparin-induced thrombocytopenia.
  • To elucidate the role of antibodies in HIT pathogenesis.
  • To outline current treatment strategies for HIT.

Main Methods:

  • Review of existing literature on heparin-induced thrombocytopenia.
  • Analysis of the immunological mechanisms underlying type II HIT.
  • Clinical case review and treatment outcome assessment.

Related Experiment Videos

Main Results:

  • Type II HIT is primarily mediated by antibodies targeting the heparin-platelet factor 4 complex.
  • This antibody-complex activates platelets and endothelial cells, promoting thrombosis.
  • Clinical manifestations include both arterial and venous thrombosis.

Conclusions:

  • Discontinuation of heparin is essential for managing HIT.
  • Alternative anticoagulation is required for patients with HIT.
  • Understanding the immune mechanism is crucial for effective HIT management.